| Hypertensive disease
Epaned vs Qbrelis
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Epaned vs Qbrelis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQbrelis has a higher rate of injection site reactions vs Epaned based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qbrelis but not Epaned, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Epaned
Qbrelis
At A Glance
Oral
Once or twice daily
ACE inhibitor
Oral
Once daily
ACE inhibitor
Indications
- Hypertensive disease
- Heart failure
- Ventricular Dysfunction, Left
- Hypertensive disease
- Heart Failure, Systolic
- Acute myocardial infarction
Dosing
Hypertensive disease Adults: 5 mg once daily orally, titrated up to 40 mg daily; pediatric patients >1 month: 0.08 mg/kg (up to 5 mg) once daily; renal impairment (GFR <=30 mL/min) or dialysis: initial dose 2.5 mg daily.
Heart failure 2.5 mg twice daily orally, titrated up to 20 mg twice daily as tolerated; usually given in combination with diuretics and digitalis.
Ventricular Dysfunction, Left 2.5 mg twice daily orally, titrated up to 10 mg twice daily as tolerated.
Hypertensive disease Adults: initial 10 mg once daily (5 mg once daily if on diuretics), titrate to 20-40 mg once daily; pediatric patients >=6 years with GFR >30 mL/min/1.73m2: initial 0.07 mg/kg (up to 5 mg) once daily, maximum 0.61 mg/kg (up to 40 mg) once daily, oral.
Heart Failure, Systolic Initial 5 mg once daily (2.5 mg once daily if hyponatremia present) with diuretics and digitalis; increase as tolerated to 40 mg once daily, oral.
Acute myocardial infarction 5 mg within 24 hours of onset, then 5 mg at 24 hours, then 10 mg once daily for at least 6 weeks; initiate at 2.5 mg once daily if systolic BP <=120 mmHg, oral.
Contraindications
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril), or within 36 hours of switching to or from sacubitril/valsartan
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril); do not administer within 36 hours of switching to or from sacubitril/valsartan
Adverse Reactions
Most common (>1%) Fatigue, orthostatic effects, asthenia, cough, rash; in heart failure patients: hypotension, dizziness.
Serious Angioedema, hypotension, hepatic failure, renal impairment, hyperkalemia, cardiac arrest, myocardial infarction, cerebrovascular accident, neutropenia, thrombocytopenia, bone marrow depression.
Postmarketing Pancreatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, eosinophilic pneumonitis, pulmonary infiltrates, gynecomastia.
Most common (>=2%) Hypertension: headache, dizziness, cough; Heart Failure: hypotension, chest pain; Acute MI: hypotension.
Serious Bone marrow depression, hemolytic anemia, leukopenia/neutropenia, thrombocytopenia, toxic epidermal necrolysis, Stevens-Johnson syndrome, pancreatitis, hyperkalemia, renal dysfunction.
Postmarketing Hyponatremia, hypoglycemia in diabetic patients, mood alterations, mental confusion, hallucinations, psoriasis.
Pharmacology
ACE inhibitor; enalapril is hydrolyzed to enalaprilat, which inhibits angiotensin-converting enzyme, suppressing the renin-angiotensin-aldosterone system and thereby reducing plasma angiotensin II, vasopressor activity, and aldosterone secretion.
ACE inhibitor; lisinopril inhibits angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II, thereby decreasing vasopressor activity and aldosterone secretion to lower blood pressure in hypertension, heart failure, and post-myocardial infarction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Epaned
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Qbrelis
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Epaned
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Qbrelis
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Epaned
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Qbrelis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Epaned.
No savings programs available for Qbrelis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EpanedView full Epaned profile
QbrelisView full Qbrelis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.